SEARCH

SEARCH BY CITATION

References

  • 1
    Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Lancet. 1991;338:3558.
  • 2
    Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799809.
  • 3
    Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:917.
  • 4
    Ylitalo R, Monkkonen J, Urtti A, Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med. 1996;127:2006.
  • 5
    Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colón-Emeric CS. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res. 2013;28:984991.
  • 6
    Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho GTPase. J Biol Chem. 1998;273:2426671.
  • 7
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:75665.
  • 8
    Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010;95:117481.
  • 9
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:180922.
  • 10
    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su GQ, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367:171423.
  • 11
    Million Women Study Collaborators Patterns of use of hormone replacement therapy in one million women in Britain, 1996–2000. BJOG. 2002;109:131930.
  • 12
    Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium/vitamin D supplements and cardiovascular events: a re-analysis of the Women's Health Initiative limited-access dataset, and meta-analysis of calcium with or without vitamin D. BMJ. 2011;342:d2040.
  • 13
    Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:32133.
  • 14
    Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson JE, Robins J. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:76679.
  • 15
    Bolland MJ, Avenell A, Baron JA, Grey AB, MacLennan GS, Gamble GD, Reid IR. Effect of calcium supplements on the risk of myocardial infarction and cardiovascular events: a meta-analysis. BMJ. 2010;341:c3691.
  • 16
    Pentti K, Tuppurainen MT, Honkanen R, Sandini L, Kroger H, Alhava E, Saarikoski S. Use of calcium supplements and the risk of coronary heart disease in 52–62-year-old women: The Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas. 2009;63:738.
  • 17
    Li KR, Kaaks R, Linseisen J, Rohrmann S. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart. 2012;98:9205.
  • 18
    Samelson EJ, Booth SL, Fox CS, Tucker KL, Wang TJ, Hoffmann U, Cupples LA, O'Donnell CJ, Kiel DP. Calcium intake is not associated with increased coronary artery calcification: the Framingham Study. Am J Clin Nutr. 2012 Dec; 96(6):127480.
  • 19
    Paik J, Curhan G, Rexrode K, Manson J, Eric R, Taylor E. A prospective study of calcium supplement intake and risk of cardiovascular disease in women. J Bone Miner Res. 2012; 27 (Suppl 1):S45.
  • 20
    Michaëlsson K, Melhus H, Lemming EW, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013;346:f228.
  • 21
    Xiao Q, Murphy RA, Houston DK, Harris TB, Chow W-H, Park Y. Dietary and supplemental calcium intake and cardiovascular disease mortality. The National Institutes of Health–AARP Diet and Health Study. JAMA Intern Med. 2013 Feb 4:18.
  • 22
    Ioannidis JPA. The importance of potential studies that have not existed and registration of observational data sets. JAMA. 2012;308:5756.
  • 23
    Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet. 2004;363:172831.
  • 24
    Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes. J Am Dent Assoc. 2008;139:2330.
  • 25
    Pazianas M, Blumentals WA, Miller PD. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2008;19:7739.
  • 26
    Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT. A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol. 2012;30:322933.
  • 27
    Abrahamsen B, Pazianas M, Eiken P, Russell RGG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. 2012;27:67986.
  • 28
    Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011 May 5; 364(18):172837. [Errata: N Engl J Med. 2011 Oct 20;365(16):1551. N Engl J Med. 2012 Aug 9;367(6):582.]
  • 29
    Meier RPH, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172:9306.